Paraganglioma Tumor Survival Rate: A Detailed Look

Survival after a paraganglioma diagnosis varies enormously depending on whether the tumor is localized or has spread. Most paragangliomas are slow-growing and non-metastatic, and people with those tumors often live decades with excellent survival rates. Even when these tumors do metastasize, median overall survival from diagnosis can stretch beyond 10 years in some series, though the picture becomes far more complicated once genetics, tumor location, and treatment response enter the equation.

What a Paraganglioma Is and Why “Survival Rate” Means Different Things

Paragangliomas are rare neuroendocrine tumors that arise from clusters of nerve tissue scattered throughout the body. When they develop in the adrenal gland, they are called pheochromocytomas; when they appear outside the adrenal gland, along the spine, in the abdomen, or in the head and neck, they are called paragangliomas. Researchers and clinicians often group them together under the umbrella term PPGL (pheochromocytoma and paraganglioma) because their biology overlaps substantially. However, survival statistics can look very different depending on whether you are reading about a localized head and neck tumor, a benign adrenal pheochromocytoma, or a metastatic abdominal paraganglioma. That distinction matters more than almost anything else when interpreting the numbers.

Head and neck paragangliomas tend to be the slowest-growing of the group. They rarely produce the catecholamine surges that make adrenal tumors dangerous, and when they do spread, patients with metastatic head and neck paragangliomas have been reported to have a median disease-specific survival of over 33 years, compared with roughly 20 years for metastatic sympathetic (body) PPGLs.¹ That gap is enormous and underscores why a single “paraganglioma survival rate” can be misleading.

Overall Survival Numbers for Metastatic Disease

The subset of paragangliomas that receives the most research attention is metastatic PPGL, because those tumors pose the greatest clinical challenge. A large study following 272 patients with malignant PPGL over 55 years found a median overall survival of roughly 25 years from diagnosis, with five-year overall survival around 85%, ten-year survival around 73%, and fifteen-year survival about 65%.² Those figures may sound surprisingly favorable for a malignant tumor, and they reflect the often indolent pace of the disease. Not every metastatic PPGL behaves aggressively.

Smaller, single-institution series paint a somewhat less optimistic picture. One 20-year review of 15 patients with metastatic or recurrent PPGL reported five-, ten-, and fifteen-year survival rates of about 73%, 63%, and 31%, with a median overall survival of 11 years.³ The spread between studies reflects real differences in patient populations, referral patterns, and the era of treatment. What is consistent across the literature is that many patients live well beyond five years even after metastases are identified, but a meaningful fraction experience aggressive disease that shortens survival considerably.

Factors That Predict Who Does Well and Who Does Not

Several clinical features reliably predict shorter survival. In a large analysis, older age at diagnosis, the presence of metastases at the time of initial presentation (synchronous metastases), a tumor located outside the adrenal gland, and elevated levels of specific catecholamine metabolites in the blood were all independently linked to worse outcomes.¹ Among patients with metastatic disease specifically, synchronous metastases carried nearly a fivefold higher risk of shorter disease-specific survival compared with metastases discovered later, and a high overall metastatic burden roughly doubled the risk.

One biomarker that deserves special mention is plasma methoxytyramine, a metabolite of dopamine. In one study it was the only independent predictor of disease-specific survival among patients with head and neck paragangliomas, and it also predicted worse outcomes in patients with metastatic sympathetic PPGLs.¹ Elevated methoxytyramine often signals a dopamine-secreting tumor, a subtype with a reputation for aggressive behavior.

The Genetics Factor, Especially SDHB

Roughly 40% of paragangliomas are linked to an inherited genetic mutation, and which gene is involved has real consequences for prognosis. The most concerning is a mutation in the SDHB gene, which encodes part of the mitochondrial enzyme succinate dehydrogenase. SDHB-mutated tumors carry a substantially higher risk of becoming metastatic and tend to have worse survival compared with tumors caused by other mutations or no known mutation at all.

A National Institutes of Health study found that patients with metastatic SDHB-mutated PPGLs had five-year survival of about 92% and ten-year survival of roughly 76%, compared with about 95% and 86% in patients with other (apparent sporadic) tumors.⁴ The difference was statistically significant and persisted across age groups, though children with SDHB mutations fared better than adults with the same mutation.

A separate meta-analysis looked at SDHB mutation carriers who were identified through family screening rather than because they already had symptoms. Among those carriers who did develop tumors, the pooled risk of those tumors becoming metastatic was about 9%, though with wide uncertainty.⁵ That number is lower than the frequently cited figures of 30% or more seen in clinical series, because clinical series are enriched with people who came to attention precisely because their tumors were already problematic. The true lifetime risk for a randomly discovered SDHB carrier is lower, though not negligible, and it underscores the importance of how these numbers are measured.

Pathology Scoring Systems and Their Limits

One frustrating aspect of paraganglioma management is that pathologists cannot reliably tell from looking at a tumor under a microscope whether it will metastasize. Unlike many cancers, there is no universally accepted grading system that cleanly separates benign from malignant PPGLs. Two scoring systems have received the most study: PASS (Pheochromocytoma of the Adrenal Gland Scaled Score) and GAPP (Grading system for Adrenal Pheochromocytoma and Paraganglioma).

GAPP has shown more consistent predictive ability. In one comparison, a moderately differentiated GAPP score was associated with more than threefold higher risk of disease recurrence, while PASS did not significantly predict recurrence.⁶ A separate validation study found that a modified version of GAPP incorporating SDHB immunostaining performed best among the three scoring systems tested for predicting metastasis.⁷ SDHB loss at the protein level and extra-adrenal tumor location were among the strongest individual predictors of recurrence in multivariate analysis, alongside a higher Ki-67 proliferation index.⁶

How Surgery Affects Survival

Surgery is the primary treatment for paragangliomas whenever possible, and the data on its survival benefit in metastatic disease are striking. A study of 116 patients with metastatic pheochromocytoma or sympathetic paraganglioma found that patients who underwent surgical resection of their primary tumor had a median survival of about 148 months (roughly 12 years), compared with 36 months (3 years) in patients who did not have surgery.⁸ Even among patients who already had metastases at diagnosis, those who had surgery lived a median of 85 months versus 36 months for those who did not. The two groups had similar functional status, which helps address the concern that healthier patients simply got more surgery.

When surgeons can achieve a complete resection with clear margins, outcomes improve further. One series reported a median disease-free survival of about 4.6 years after complete resection, with some patients remaining disease-free for over a decade.⁹ Complete resection was achievable in about 41% of patients in that series, highlighting that many metastatic PPGLs are not fully resectable.

Radiation for Head and Neck Paragangliomas

For paragangliomas in the head and neck, radiation therapy is often used instead of or after surgery, particularly when a tumor wraps around critical blood vessels or cranial nerves. The local control rates are excellent. A 45-year experience with conventional radiotherapy for benign head and neck paragangliomas reported local control of 99% at five years and 96% at ten years, with cause-specific survival of 98% and 97% at those same time points.¹⁰

Stereotactic radiosurgery, a more focused form of radiation delivered in fewer sessions, has also demonstrated strong results. A systematic review and meta-analysis found a local control rate of about 94% with a median follow-up of nearly four years.¹¹ These high control rates hold even in patients with hereditary SDHx-related paragangliomas, where radiosurgery appears to provide durable control across the major genetic subtypes.¹²

The critical caveat is that radiation controls local growth but does not cure the underlying genetic predisposition. Patients with hereditary forms can develop new tumors at other sites over time, which is why surveillance remains essential even after successful local treatment.

Radionuclide Therapies for Metastatic Disease

When metastatic paragangliomas cannot be removed surgically, two forms of targeted radiation delivered internally have shown meaningful activity. The older approach uses radioactive iodine-131 MIBG, which is taken up by catecholamine-producing cells. In a study of 125 patients treated with I-131 MIBG, median survival from diagnosis was about 11.5 years, with median survival after treatment of roughly 4.3 years.¹³

The newer approach is peptide receptor radionuclide therapy (PRRT) using lutetium-177 DOTATATE, which targets somatostatin receptors on the tumor surface. Multiple small studies have reported encouraging results. One found a median overall survival of about 55 months and median progression-free survival of roughly 27 months, with a disease control rate of 73%.¹⁴ A separate single-center analysis reported similar progression-free survival of about 24 months for the overall cohort.¹⁵ Among patients whose disease had been progressing before PRRT, roughly 63% achieved either stability or partial response, suggesting the treatment can meaningfully slow disease in a majority of patients.¹⁴

Chemotherapy and Newer Targeted Drugs

Traditional chemotherapy for metastatic PPGL centers on the CVD regimen: cyclophosphamide, vincristine, and dacarbazine. In a 22-year follow-up of 18 patients, CVD produced partial or complete tumor shrinkage in about 55% of patients. However, the median survival was 3.8 years for responders and 1.8 years for non-responders, and that difference was not statistically significant, meaning tumor shrinkage did not clearly translate into longer life.¹⁶ One intriguing finding from a separate analysis was that patients with SDHB mutations appeared to respond better to CVD, with a median progression-free survival of nearly 24 months compared with about 5 months in non-SDHB patients.¹⁷ That result needs confirmation in larger studies, but it hints at how genetic subtyping could guide treatment choices.

The targeted therapy landscape has shifted significantly in recent years. The FIRSTMAPPP trial tested sunitinib, a drug that blocks blood vessel growth, in patients with progressive metastatic PPGL. About 36% of sunitinib-treated patients were progression-free at 12 months, compared with 19% on placebo.¹⁸ The effect was modest but real, and sunitinib remains one of the few drugs tested in a randomized controlled trial for this disease.

The most promising recent development is belzutifan, a drug that targets the hypoxia pathway, which is abnormally activated in many PPGLs. In a phase 2 trial, belzutifan achieved an objective response rate of 26%, disease control in 85% of patients, and a median progression-free survival of over 22 months.¹⁹ The median duration of response exceeded 20 months. For a disease with no FDA-approved systemic therapy until very recently, those numbers represent a meaningful step forward.

Early data on immunotherapy have been less encouraging. A small trial of pembrolizumab, an immune checkpoint inhibitor, showed a partial response in only one of eleven evaluable patients, though about 64% had stable disease. The median progression-free survival was under 6 months, and median overall survival was 19 months.²⁰ Immunotherapy remains an area of active investigation but has not yet proven itself in PPGL the way it has in some other cancers.

Paraganglioma in Children

PPGLs are rare in children, but they do occur and tend to be more frequently hereditary. A French series of pediatric patients found that overall survival was remarkably high at 97% at both three and ten years. Event-free survival, however, was far lower: about 80% at three years, 61% at five years, and just 39% at ten years.²¹ That gap between overall survival and event-free survival tells you that children rarely die of this disease, but they frequently experience recurrences or new tumor events over time. Late events beyond five years occurred in about a quarter of those who had any event at all, and incomplete initial surgical resection and metastatic disease at diagnosis were both associated with higher relapse risk.

The NIH data mentioned earlier found that children with SDHB mutations had significantly longer survival than adults with the same mutation.⁴ The reasons are not entirely clear, but the overall message is that pediatric PPGL, while prone to recurrence, rarely behaves as a lethal disease in childhood.

Cardiovascular Complications and Non-Cancer Mortality

Survival statistics for paragangliomas sometimes overlook an important contributor to poor outcomes: the cardiovascular damage caused by excess catecholamine production. PPGL-induced cardiomyopathy occurs in up to about 11% of cases, predominantly with adrenal pheochromocytomas. The prognosis is worse in patients whose heart damage develops gradually rather than acutely, with higher rates of cardiogenic shock and lower rates of heart function recovery after tumor removal.²² For some patients, particularly those whose diagnosis is delayed, the heart damage can be the more immediate threat to survival, separate from the tumor’s malignant potential.

Pregnancy and Paragangliomas

Paragangliomas discovered during pregnancy present a rare but high-stakes clinical scenario. The catecholamine surges can provoke dangerously high blood pressure, which threatens both the pregnant person and the fetus. A case series and literature review found that good maternal and fetal outcomes are achievable with individualized care from a multidisciplinary team, but the condition carries real morbidity and mortality risk if unrecognized.²³ Women with known hereditary PPGL syndromes are typically counseled about this risk before conception.

Quality of Life After Treatment

Survival statistics do not capture the full picture of living with a paraganglioma, particularly for head and neck tumors where surgery can damage cranial nerves. A study assessing quality of life after surgical treatment found that the highest symptom burdens were fear of disease progression, dry mouth, problems with sexuality, and difficulty swallowing.²⁴ The impact varied substantially by tumor location. Patients who had carotid body tumors removed reported the fewest functional problems, while those treated for vagal or jugular paragangliomas experienced significantly more difficulty with swallowing, speech, and social eating. Patients who already had nerve palsies before surgery reported markedly worse quality of life in several domains.

A scoping review confirmed that head and neck paragangliomas negatively affect quality of life even in patients who do not undergo intervention, and that patients with multiple tumors or voice problems reported disproportionately lower scores.²⁵ For a disease where survival is often measured in decades, the quality of those decades matters immensely, and treatment decisions often involve weighing the risk of nerve injury from surgery against the risk of tumor growth over time.

Why Lifelong Follow-Up Is Not Optional

One of the more unsettling aspects of paraganglioma biology is the potential for extremely late recurrence. A case report documented a recurrence more than 30 years after initial surgical resection, reinforcing current guideline recommendations for lifelong biochemical and imaging surveillance.²⁶ The pediatric data tell a similar story: late events after five years were not uncommon, occurring in about a quarter of children who experienced any disease event.²¹

This is especially relevant for patients with hereditary mutations, who can develop entirely new primary tumors at different sites years or decades later. Annual or biannual biochemical screening, typically measuring catecholamine metabolites in blood or urine, combined with periodic imaging, forms the backbone of long-term follow-up. Skipping surveillance because you feel well is risky with a tumor that can stay silent for years before reappearing.

1
European Journal of Cancer. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma
2
The Journal of Clinical Endocrinology & Metabolism. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
3
Scientific Reports. Long-term outcomes and prognostic factors of metastatic or recurrent pheochromocytoma and paraganglioma: a 20-year review in a single institution
4
PubMed Central. CHARACTERISTICS AND OUTCOMES OF METASTATIC SDHB AND SPORADIC PHEOCHROMOCYTOMA/PARAGANGLIOMA: AN NATIONAL INSTITUTES OF HEALTH STUDY
5
The Journal of Clinical Endocrinology & Metabolism. Outcomes of SDHB Pathogenic Variant Carriers
6
PubMed Central. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems
7
PLoS ONE. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma
8
PubMed. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma
9
PubMed. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series
10
PubMed. Radiotherapy for benign head and neck paragangliomas: a 45-year experience
11
PubMed. Stereotactic radiosurgery for head and neck paragangliomas: a systematic review and meta-analysis
12
PubMed. Radiosurgical management of SDHx-related paraganglioma
13
PubMed Central. Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG
14
Journal of Nuclear Medicine. Outcomes of Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Patients with Metastatic Pheochromocytoma and Paraganglioma
15
PubMed Central. 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence
16
PubMed Central. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients
17
Endocrine-Related Cancer. SDHB mutation carriers with malignant pheochromocytoma respond better to CVD
18
PubMed. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
19
The New England Journal of Medicine. Belzutifan for Advanced Pheochromocytoma or Paraganglioma
20
PubMed Central. Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
21
PubMed Central. Pheochromocytoma and Paraganglioma in Children and Adolescents: Experience of the French Society of Pediatric Oncology (SFCE)
22
PubMed Central. Pheochromocytoma/paraganglioma-associated cardiomyopathy
23
PubMed Central. Paraganglioma in pregnancy: A case series and literature review
24
PubMed Central. Quality of Life After Surgical Treatment of Head and Neck Paragangliomas
25
PubMed Central. Mapping the neglected topic in head and neck paraganglioma research: a PRISMA scoping review on quality of life
26
Endocrine Practice. Late Recurrence of Pheochromocytoma/Paraganglioma Over 3 Decades After Initial Resection